Products
Bextra film-coated tablets are no longer on the market in many countries. Approval was withdrawn in April 2005 because rare severe skin reactions had occurred during treatment (see below).
Structure and properties
Valdecoxib (C16H14N2O3S, Mr = 314.4 g/mol) is a phenylisoxazole and a benzenesulfonamide derivative. It has a V-shaped structure with which it binds to the Active Site of the drug target. Valdecoxib exists as a white crystalline powder and is practically insoluble in water.
Effects
Valdecoxib (ATC M01AH03) has analgesic and anti-inflammatory properties. The effects are due to selective inhibition of the enzyme cyclooxygenase-2 (COX-2) and inhibition of the synthesis of prostaglandins.
Indications
- Osteoarthritis
- Rheumatoid arthritis
- Acute pain
- Menstrual pain
Adverse effects
During treatment, severe skin reactions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme were rare. In addition, as with other COX-2 inhibitors, there were concerns about cardiovascular safety.
